論文

査読有り 国際誌
2017年2月

A randomized double-blind trial of intravenous immunoglobulin for bullous pemphigoid.

Journal of dermatological science
  • Masayuki Amagai
  • Shigaku Ikeda
  • Takashi Hashimoto
  • Masato Mizuashi
  • Akihiro Fujisawa
  • Hironobu Ihn
  • Yasushi Matsuzaki
  • Mikio Ohtsuka
  • Hiroshi Fujiwara
  • Junichi Furuta
  • Osamu Tago
  • Jun Yamagami
  • Akiko Tanikawa
  • Hisashi Uhara
  • Akimichi Morita
  • Gen Nakanishi
  • Mamori Tani
  • Yumi Aoyama
  • Eiichi Makino
  • Masahiko Muto
  • Motomu Manabe
  • Takayuki Konno
  • Satoru Murata
  • Seiichi Izaki
  • Hideaki Watanabe
  • Yukie Yamaguchi
  • Setsuko Matsukura
  • Mariko Seishima
  • Koji Habe
  • Yuichi Yoshida
  • Sakae Kaneko
  • Hajime Shindo
  • Kimiko Nakajima
  • Takuro Kanekura
  • Kenzo Takahashi
  • Yasuo Kitajima
  • Koji Hashimoto
  • 全て表示

85
2
開始ページ
77
終了ページ
84
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.1016/j.jdermsci.2016.11.003

BACKGROUND: Patients with steroid-resistant bullous pemphigoid (BP) require an appropriate treatment option. OBJECTIVE: A multicenter, randomized, placebo-controlled, double-blind trial was conducted to investigate the therapeutic effect of high-dose intravenous immunoglobulin (IVIG; 400mg/kg/day for 5days) in BP patients who showed no symptomatic improvement with prednisolone (≥0.4mg/kg/day) administered. METHODS: We evaluated the efficacy using the disease activity score on day15 (DAS15) as a primary endpoint, and changes in the DAS over time, the anti-BP180 antibody titer, and safety for a period of 57days as secondary endpoints. RESULTS: We enrolled 56 patients in this study. The DAS15 was 12.5 points lower in the IVIG group than in the placebo group (p=0.089). The mean DAS of the IVIG group was constantly lower than that of the placebo group throughout the course of observation, and a post hoc analysis of covariance revealed a significant difference (p=0.041). Furthermore, when analyzed only in severe cases (DAS≥40), the DAS15 differed significantly (p=0.046). The anti-BP180 antibody titers showed no difference between the two groups. CONCLUSION: IVIG provides a beneficial therapeutic outcome for patients with BP who are resistant to steroid therapy.

リンク情報
DOI
https://doi.org/10.1016/j.jdermsci.2016.11.003
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/27876358
ID情報
  • DOI : 10.1016/j.jdermsci.2016.11.003
  • ISSN : 0923-1811
  • PubMed ID : 27876358

エクスポート
BibTeX RIS